Company Analysis
Sign in

Tvardi Therapeutics, Inc. (TVRD)

Nasdaq: TVRD · Pharmaceutical Preparations · Sugar Land, TX · filing with the SEC since 2005
Full chart Alerts Compare
Grade4.2
◀ Past 4.7● Present 3.5▶ Future 4.7
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

37 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tvardi Therapeutics, Inc.’s names, not what it holds today.

Patents granted
37
37 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and 3 in 2023
Applications published
55
2 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'10'11'12'13'14'15'16'17'18'19'20'21'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Cara Therapeutics, Inc. a former name
US, as the owner printed on each patent
31 granted
39 published
Tvardi Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
12 published
Tvardi Therapeutics, Inc. its own name
US, as the owner printed on each patent
6 granted
0 published
Cara Therapeutics, Inc. a former name
named as the applicant on its applications, in US
0 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 6, 202412,053,444Therapeutic compounds, formulations, and uses thereofPharmaceuticalsTvardi Therapeutics, Inc.
Jul 23, 202412,043,640Prodrugs of STAT3 inhibitorsOrganic fine chemistryTvardi Therapeutics, Inc.
May 21, 202411,986,509Oligosaccharide formulations of kappa opioid receptor agonistsPharmaceuticalsCara Therapeutics, Inc.
Nov 28, 202311,826,315STAT3 inhibitorsPharmaceuticalsTvardi Therapeutics, Inc.
Jun 27, 202311,684,674Oral formulations of kappa opioid receptor agonistsPharmaceuticalsCara Therapeutics, Inc.
Jan 10, 202311,547,683Therapeutic compounds, formulations, and uses thereofPharmaceuticalsTvardi Therapeutics, Inc.
Aug 3, 202111,077,077Therapeutic compounds, formulations, and uses thereofPharmaceuticalsTvardi Therapeutics, Inc.
Jun 15, 202111,033,629Oral formulations of kappa opioid receptor agonistsPharmaceuticalsCara Therapeutics, Inc.
Jun 8, 202111,026,905STAT3 inhibitorsPharmaceuticalsTvardi Therapeutics, Inc.
Feb 9, 202110,913,769Synthetic peptide amides and dimers thereofPharmaceuticalsCara Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
May 29, 20252025/0170079COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCERPharmaceuticalsTvardi Therapeutics, Inc.
May 29, 20252025/0170065THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOFPharmaceuticalsTvardi Therapeutics, Inc.
Oct 3, 20242024/0327438PRODRUGS OF STAT3 INHIBITORSOrganic fine chemistryTvardi Therapeutics, Inc.
Feb 22, 20242024/0058284STAT3 INHIBITORSPharmaceuticalsTvardi Therapeutics, Inc.
Feb 1, 20242024/0033234THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOFOrganic fine chemistryTvardi Therapeutics, Inc.
Jan 18, 20242024/0018172PRODRUGS OF STAT3 INHIBITORSOrganic fine chemistryTvardi Therapeutics, Inc. · patent 12,043,640 granted from it
Nov 30, 20232023/0381265OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTSPharmaceuticalsCara Therapeutics, Inc.
Oct 26, 20232023/0338546ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTSPharmaceuticalsCara Therapeutics, Inc.
Oct 12, 20232023/0321265KAPPA OPIOID RECEPTOR AGONIST-THERAPEUTIC ANTIGEN BINDING PROTEIN CONJUGATE (KTAC) COMPOUNDSPharmaceuticalsCara Therapeutics, Inc.
Sep 14, 20232023/0285497ATOPIC DERMATITIS THERAPY WITH KAPPA OPIOID RECEPTOR AGONIST AS ADJUNCT TO TOPICAL CORTICOSTEROIDPharmaceuticalsCara Therapeutics, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 3 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TVRD · research, not advice